Showing 1,541 - 1,560 results of 121,138 for search '(( 2 e decrease ) OR ( 5 ((((teer decrease) OR (a decrease))) OR (nn decrease)) ))', query time: 1.84s Refine Results
  1. 1541

    Statins impact primary embryonic mouse neural stem cell survival, cell death, and fate through distinct mechanisms by Ross A. Carson (5184512)

    Published 2018
    “…Genome-wide transcriptome analysis demonstrates an increase in expression of CBP genes following pravastatin treatment, through activation of the SREBP2 transcription factor. Co-treatment with farnesyl pyrophosphate (FPP), a CBP metabolite downstream of HMG-CoA reductase, reduces SREBP2 activation and pravastatin-induced PARP cleavage. …”
  2. 1542
  3. 1543
  4. 1544
  5. 1545
  6. 1546
  7. 1547
  8. 1548
  9. 1549
  10. 1550

    Response of small airway tissues infected with EV-D94 and decreasing doses of EV-D68. by Ines Cordeiro Filipe (5849144)

    Published 2022
    “…<p>Tissues were infected with 1E7 RNA copies of EV-D94 (equivalent to 2,46E4 TCID50) and 1E7 RNA copies of EV-D68 (3,3E5 TCID50) as well as decreasing doses of the latter. …”
  11. 1551
  12. 1552

    A decrease in the invasiveness of <i>Candida albicans</i> into Caco-2 cells parallels the differentiation of intestinal epithelial cells. by Marianne Goyer (2550589)

    Published 2016
    “…Caco-2 cell differentiation increased throughout the culture as highlighted by the increase in TEER measurements (Ω.cm<sup>2</sup>) (full line), which correlated with a decrease in <i>C</i>. …”
  13. 1553
  14. 1554
  15. 1555
  16. 1556
  17. 1557
  18. 1558
  19. 1559
  20. 1560

    S5 Raw image - by Zhi Xuan Low (19270163)

    Published 2024
    “…Furthermore, the inclusion complex exhibited reduced systemic toxicity, including reduced inflammation in vital organs as examined by hematoxylin and eosin (H&E) staining. This study also revealed a notable sequential reduction in serum levels of tumour markers, including carcinoembryonic antigen (CEA) and mouse Cytochrome P450 1A2 (CYP1A2), correlating with a significant decrease in tumour bulk volume upon treatment commencement. …”